Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Alzheimer Disease l: Introduction

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...

Alzheimer Disease ll: Pathophysiology

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...

Dementia l: Introduction

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...

Huntington Disease l: Introduction

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

Preconception cardiometabolic markers and odds of developing adverse pregnancy outcomes: Results from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL).

American journal of preventive cardiology·2026

Same author

Planetary Boundary for Novel Entities: Time for a Reboot.

Environmental science & technology·2026

Same author

A scalable, dividing cell model for the robust propagation and quantification of human sporadic Creutzfeldt-Jakob disease prions.

Proceedings of the National Academy of Sciences of the United States of America·2026

Same author

Aerobic Fitness Is the Main Determinant of Match-Related Physical Performance Decline in Professional Football Players (Part 2).

Journal of strength and conditioning research·2026

Same author

Availability of mechanical circulatory support (MCS) and hospital survival in ST-segment elevation myocardial infarction related cardiogenic shock (STEMI-CS).

European heart journal. Acute cardiovascular care·2026

Search research articles

Related Experiment Video

Updated: May 29, 2026

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Published on: March 22, 2016

Rapidly progressive Alzheimer disease.

Christian Schmidt¹, Martin Wolff, Michael Weitz

¹Dementia Research Unit, Department of Neurology, Georg-August-Universität Göttingen, Göttingen, Germany. christian.schmidt@medizin.uni-goettingen.de

Archives of Neurology

|September 14, 2011

Summary

Rapidly progressive Alzheimer disease (AD) involves faster cognitive decline. This review defines rapid AD progression as a Mini-Mental State Examination score decrease of 6 points annually, exploring contributing factors.

More Related Videos

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on ¹⁸F-AV-1451

Published on: April 18, 2025

Related Experiment Videos

Last Updated: May 29, 2026

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Published on: March 22, 2016

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on ¹⁸F-AV-1451

Published on: April 18, 2025

Area of Science:

Neurology
Neuroscience
Geriatrics

Background:

Alzheimer disease (AD) progression varies significantly among patients.
Identified risk factors for accelerated AD deterioration include genetics, comorbidities, and early motor signs.
Rapid AD forms present with swift cognitive decline and short disease durations.

Purpose of the Study:

To review current knowledge on rapidly progressive Alzheimer disease.
To propose a standardized definition for rapid AD progression.

Main Methods:

Literature review of studies on Alzheimer disease progression.
Analysis of risk factors associated with accelerated cognitive decline.
Proposal of a quantitative definition for rapid AD progression.

Main Results:

Varied progression rates are characteristic of Alzheimer disease.
Genetics, comorbidity, and early motor symptoms are implicated in faster AD decline.
A significant decrease in Mini-Mental State Examination (MMSE) scores indicates rapid progression.

Conclusions:

Rapid Alzheimer disease is characterized by accelerated cognitive deterioration.
A decrease of 6 points per year in MMSE score is proposed as a definition for rapid AD.
Further research is needed to fully understand and manage rapidly progressive Alzheimer disease.